Dr Reddys Laboratories

1,196.10
-6.10
(-0.51%)
hide
Key Fundamentals
Add Ratio
Market Cap
99,828.15 Cr
EPS
67.89
PE Ratio
17.49
Dividend Yield
0.66 %
Industry
Healthcare
52 Week High
1,405.90
52 Week Low
1,020.00
PB Ratio
2.79
Debt to Equity
0.11
Forecast For
Actual

Company News

View All News
Caret
neutral
Dr. Reddy's Laboratories delivered consolidated revenues of ₹8,805 crores ($992 million) in Q2 FY26, marking 9.8% year-over-year growth despite pressure from lower Lenalidomide sales and product-specific price erosion in US generics. The growth was supported by the acquired consumer healthcare business and double-digit growth across other markets. EBITDA margins stood at 26.7%, while profit after tax grew 14% year-over-year to ₹1,437 crores ($162 million). The company made progress on key pipeline products with the Subject Expert Committee recommending approval for Semaglutide injection in India, and received positive opinion from European Medicines Agency for denosumab biosimilar. The India business reported strong 13% growth to ₹1,578 crores, moving up to 9th position in the Indian Pharmaceutical Market. North America generics declined 16% to $373 million due to Lenalidomide price erosion, while European generics grew 115% to €135 million driven by the acquired Nicotine Replacement Therapy portfolio. The company expects to submit Abatacept BLA by end of December 2025 and anticipates feedback on Semaglutide from Health Canada in coming weeks.
negative
Dr Reddy's Laboratories has received a notice for not complying with Canadian regulations related to semaglutide, a diabetes and weight management medication.
positive
Dr. Reddy's Labs has outlined its financial projections and strategic targets during a conference call. The company anticipates SG&A costs will be 28-30% of sales, while R&D expenses are projected to stay around 7% of sales. The pharmaceutical company plans to achieve target margins within two years, depending on the success of key products like Semaglutide and Abatacept. Dr. Reddy's is aiming for Semaglutide approvals in 87 nations within 12-15 months. The company expects gross margins between 20-25% in pharmaceutical services and active ingredients, and aims to achieve 25% EBITDA margins by FY27 despite short-term challenges from Lenalidomide decrease.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,699.20
#1 4,07,695.00
39.32
#1 54,729.00
9.71
#1 10,980
-19.84
62.54
6,696.00
1,77,757.76
76.59
9,712.00
18.67
2,191
26.74
66.75
1,507.70
1,21,785.08
22.90
28,409.50
7.12
5,291
3.71
45.05
3,589.90
1,21,498.53
60.87
11,539.40
6.99
1,911
19.91
54.91
2,425.10
1,00,098.06
52.78
12,744.20
#1 20.90
2,007
-18.14
45.57
1,196.10
#6 99,828.15
#1 17.49
#2 33,741.20
#4 16.73
#2 5,725
#7 -0.38
34.59
986.00
99,214.67
21.07
23,511.00
18.55
4,615
2.60
44.00
1,963.50
89,683.75
23.87
22,909.50
13.74
3,306
#1 51.64
49.40
1,139.80
66,199.77
19.06
32,345.60
9.43
3,484
-10.24
51.46
5,504.50
65,814.55
28.31
13,458.30
3.70
2,216
21.39
54.18
Growth Rate
Revenue Growth
16.73 %
Net Income Growth
2.64 %
Cash Flow Change
2.19 %
ROE
-14.54 %
ROCE
-13.11 %
EBITDA Margin (Avg.)
-6.42 %

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
13 Jul 2021 DIVIDEND Dividend
25.00 /share
09 Jul 2021 1,060.40 1,097.91
13 Jul 2022 DIVIDEND Dividend
30.00 /share
11 Jul 2022 781.62 896.74
12 Jul 2023 DIVIDEND Dividend
40.00 /share
11 Jul 2023 986.65 1,033.17
17 Jul 2024 DIVIDEND Dividend
40.00 /share
16 Jul 2024 1,258.69 1,329.21
29 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
29 Jul 2024 1,258.69 1,378.43
27 Jul 2024 SPLIT Split
1:5
28 Oct 2024 1,378.43 1,378.43
05 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Nov 2024 1,310.23 1,268.30
23 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jan 2025 1,343.65 1,296.25
09 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
09 May 2025 1,187.20 1,148.00
10 Jul 2025 DIVIDEND Dividend
8.00 /share
10 Jul 2025 1,148.00 1,269.40
23 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jul 2025 1,325.45 1,240.40
24 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
24 Jul 2025 1,148.00 1,247.40
24 Oct 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
24 Oct 2025 1,321.70 1,279.40

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Sundaram Large Cap Fund Direct - Growth
1.92%
-503596
-1.97%
-1.89%
Parag Parikh Flexi Cap Fund Direct-Growth
1.24%
475000
-0.04%
-0.02%
Sundaram Focused Fund Direct-Growth
1.92%
-199994
-2.39%
-2.34%
Edelweiss Balanced Advantage Fund Direct-Growth
0.00%
-155492
-0.15%
-0.62%
Aditya Birla Sun Life Quant Fund Direct-Growth
1.12%
-78822
-0.44%
-0.40%
Kotak Quant Fund Direct - Growth
0.98%
47802
0.98%
0.98%
Tata India Pharma & Healthcare Fund Direct-Growth
1.71%
-30694
-0.33%
-0.30%
UTI Retirement Fund Direct
0.40%
-30581
-0.10%
-0.09%
Baroda BNP Paribas Manufacturing Fund Direct - Growth
2.43%
-27000
-0.27%
-0.51%
Edelweiss Aggressive Hybrid Fund Direct - Growth
0.04%
-26875
-0.11%
0.04%
Nippon India Nifty 50 Value 20 Index Fund Direct - Growth
1.72%
-26528
-0.36%
-0.37%
UTI Healthcare Fund Direct-Growth
3.74%
-25000
-0.32%
-0.25%
DSP Nifty 50 Equal Weight Index Fund Direct - Growth
1.94%
23196
0.03%
0.01%
UTI Large Cap Fund Direct-Growth
1.04%
-21340
-0.05%
-0.08%
UTI BSE Low Volatility Index Fund Direct - Growth
3.16%
-21013
-0.55%
-0.55%
JM Value Fund Direct Plan-Growth
1.54%
20000
0.23%
0.82%
Edelweiss Large Cap Fund Direct -Growth
0.06%
-18750
-0.19%
-0.46%
HDFC NIFTY50 Equal Weight Index Fund Direct - Growth
1.94%
16899
0.03%
0.01%
Parag Parikh ELSS Tax Saver Fund Direct - Growth
1.25%
13500
-0.03%
-0.04%
PGIM India Balanced Advantage Fund Direct - Growth
1.11%
-11487
-0.17%
-0.16%
UTI Nifty 50 Index Fund Direct-Growth
0.66%
9973
-0.03%
-0.03%
Nippon India Nifty Alpha Low Volatility 30 Index Fund Direct - Growth
3.64%
-9617
-0.09%
-0.07%
ITI Pharma and Healthcare Fund Direct - Growth
2.45%
8900
0.43%
1.29%
UTI Equity Savings Fund Direct - Growth
0.48%
-8761
-0.18%
-0.19%
Bandhan Nifty100 Low Volatility 30 Index Fund Direct-Growth
3.44%
8333
-0.08%
-0.15%

Technical Indicators

RSI(14)
Neutral
34.59
ATR(14)
Less Volatile
29.22
STOCH(9,6)
Neutral
56.58
STOCH RSI(14)
Neutral
41.03
MACD(12,26)
Bearish
-2.33
ADX(14)
Weak Trend
16.80
UO(9)
Bearish
43.80
ROC(12)
Downtrend And Accelerating
-4.77
WillR(14)
Oversold
-82.64